ArticleFrontiers in endocrinology2025
Comprehensive bioinformatics analysis and experimental verification identify mitochondrial gene Dgat2 as a novel therapeutic biomarker for myocardial ischemia-reperfusion.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MITF Regulates CFTR Expression to Participate in Myocardial Ischemia-Reperfusion Injury.The journal of gene medicine · 2026Article
- Identification of LncRNA Mhrt as a potential biomarker for preventing the progression of Myocardial Ischemia-Reperfusion Injury through bioinformatics and experimental validation.BMC cardiovascular disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemic cardiomyopathy is a severe disease marked by high morbidity and mortality, often exacerbated by myocardial ischemia/reperfusion injury (MI/RI). Mitochondrial metabolism plays a critical role in MI/RI progression. This study aimed to identify potential new targets and biomarkers for mitochondria-related genes in MI/RI. Methods: MI/R microarray data (GSE160516) from the GEO database and a mitochondrial geneset were analyzed. Limma identified differentially expressed genes (DEGs), followed by GSEA, GO, and KEGG pathway enrichment. Mitochondria-related DEGs (MitoDEGs) were pinpointed. Protein-Protein Interaction (PPI) networks and machine learning identified key MitoDEGs. Regulatory networks were constructed using transcription factor (TF) predictions. Immune cell infiltration was assessed with ImmuCelAl, and correlations between MitoDEGs and immune cell levels were examined. Mouse myocardial ischemia-reperfusion models were established to validate pivotal MitoDEGs. Results: MitoDEGs were enriched in bio-oxidation, immune-inflammation, and oxidative stress pathways. Machine learning identified two hub genes: Dgat2 and Cybb. Dgat2 was significantly elevated in ischemia-reperfusion mouse models, confirmed by RT-PCR and Western blot. Functional enrichment indicated that Dgat2 may be involved in biological oxidation and lipid metabolism. TF prediction suggested PPARG as a regulator of Dgat2 expression. Immune infiltration analysis revealed significant correlations between Dgat2 and immune cells, including CD4_T_cells and NK cells, suggesting a role for immunity in MI/RI. Conclusions: We found that Dgat2 could be exploited as a novel mitochondria-related gene target and biomarker in myocardial ischemia-reperfusion injury, which is of great clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.